Time in therapeutic range: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 6: | Line 6: | ||
==Overview== | ==Overview== | ||
==Factors Affecting Time in Therapeutic Range== | ==Factors Affecting Time in Therapeutic Range (TTR)== | ||
Cross | Cross trial comparisons of TTR are hampered by variations in: | ||
===CHADS Score=== | |||
A higher [[CHADS score]] is associated with a lower TTR. Sicker patients may have reduced access to frequent testing. | |||
===Congestive Heart Failure (CHF)=== | |||
• CHF: Varying drug clearance and distribution (CHF: 63% in ROCKET, 32% RELY, 35% ARISTOTLE) | • CHF: Varying drug clearance and distribution (CHF: 63% in ROCKET, 32% RELY, 35% ARISTOTLE) | ||
Revision as of 12:44, 8 September 2011
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Synonyms and Keywords: TTR
Overview
Factors Affecting Time in Therapeutic Range (TTR)
Cross trial comparisons of TTR are hampered by variations in:
CHADS Score
A higher CHADS score is associated with a lower TTR. Sicker patients may have reduced access to frequent testing.
Congestive Heart Failure (CHF)
• CHF: Varying drug clearance and distribution (CHF: 63% in ROCKET, 32% RELY, 35% ARISTOTLE)
• Country: Highest in Scandanavia, lowest in developing countries
• What is the TTR in ROCKET AF in those countries who conducted RE-LY and vice versa (adjusting for the number of sites in each country)?
• Should trials only be conducted in countries with a high TTR or should sponsors conduct real world trials throughout the world?